News & Trends - Pharmaceuticals
Takeda’s $200 million loss as Novartis withdraws marketing application
Takeda announced the anticipated financial loss from Novartis’ withdrawal of the marketing application for Xiidra.
Xiidra (lifitegrast ophthalmic solution 5%) is the first and only prescription treatment approved by the U.S. Food and Drug Administration for both signs and symptoms of moderate- severe dry eye disease, with a mechanism of action that targets inflammation. It was one of the products obtained through the acquisition of Shire by Takeda in January 2019.
In July 2019, Takeda completed the sale of Xiidra to Novartis for a sales price of $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone receipts, including certain sales-based milestones.
As a result of Novartis’ withdrawal of the marketing application for Xiidra in Europe, Takeda expects that the probability of receiving certain sales-based milestones may be reduced, although the total potential milestone receipts of up to $1.9 billion remain unchanged. As a result of the remeasurement, Takeda anticipates that it will recognise a loss of approximately $200 million for the three-month period ending June 30, 2020.
Takeda will continue its $10 billion of divestitures of its non-core business to pay off its merger debts.
Xiidra was registered in Australia by Shire and sponsorship transferred to Novartis in September 2019.
News & Trends - Pharmaceuticals
Medicines Australia and AusBiotech join Research Australia and Digital Health CRC in welcoming funding of national strategy for medical research and National One Stop Shop
Pharma News: Medicines Australia, AusBiotech, Research Australia and the Digital Health Cooperative Research Centre (DHCRC) applaud the funding announcement of […]
MoreNews & Trends - MedTech & Diagnostics
Health insurers clash with government on GUIs decision, prompting threat of premium hikes
MedTech & Diagnostics News: A warning of potential increases in health insurance premiums for 15 million Australians has been issued […]
MoreNews & Trends - MedTech & Diagnostics
Catheter ablation underused in atrial fibrillation despite proven efficacy
MedTech & Diagnostics News: A new study highlights that nearly half of all patients hospitalised for atrial fibrillation (AF) in […]
MoreNews & Trends - Biotechnology
How prepared are we for the next pandemic?
Biotech News: The Melbourne biotechnology community came together for a symposium hosted by BioMelbourne and mRNA Victoria, featuring specialists in […]
More